This is supported by a study on the impact of targeted treatment on direct medical costs of patients with advanced NSCLC, which showed targeted agents for patients with EGFR Mut + NSCLC lowered the mean monthly medical costs by prolonging survival and diminishing the use of other medical resources [19]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.